Solute Carrier Family 12 (SLC12) as a Potential Drug Target and Biomarker

Target Name: Solute Carrier Family 12

NCBI ID: P16317

Solute Carrier Family 12

Other Name(s): None

Solute Carrier Family 12 (SLC12) as a Potential Drug Target and Biomarker

Introduction

Solute Carrier Family 12 (SLC12) is a family of transmembrane proteins that play a crucial role in the transport of various solutes, including nucleotides, ions, and small molecules. The SLC12 family is composed of at least 15 known proteins, and its encoded genes have been implicated in various physiological processes, including cell signaling, DNA replication, and metabolism.1

Recent studies have identified SLC12 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular disorders. In this article, we will explore the biology of SLC12 and its potential as a drug target and biomarker.

Biography of SLC12

SLC12 is a transmembrane protein that belongs to the Solute Carrier Family 12. It consists of a single transmembrane domain and a cytoplasmic tail. The cytoplasmic tail is composed of an N-terminal cytoplasmic domain, a transmembrane domain, and a C-terminal protein- coding region.2

SLC12 is expressed in various tissues and cells, including muscle, heart, brain, and cancer cells. It is involved in the transport of various solutes, including nucleotides, ions, and small molecules.3

Potential Drug Target

SLC12 has been identified as a potential drug target due to its various functions in various physiological processes. One of the main reasons for its potential as a drug target is its involvement in cell signaling. SLC12 is involved in various signaling pathways, including G-protein -coupled receptor (GPCR) signaling, T-cell signaling, and neurotransmitter signaling.4

In addition to its role in cell signaling, SLC12 has also been shown to play a role in cancer progression. Studies have shown that SLC12 is involved in the transport of various cancer-promoting factors, including the oncogene badenylate.5

Potential Biomarkers

SLC12 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular disorders. One of the main reasons for its potential as a biomarker is its involvement in the transport of various solutes, which can be used as diagnostic or therapeutic targets.6

For example, SLC12 has been shown to be involved in the transport of glutamate, a well-known neurotransmitter that is involved in various cognitive and behavioral processes. 7 Studies have shown that individuals with SLC12 mutations have impaired cognitive and behavioral functions, suggesting that SLC12 may be a useful biomarker for neurodegenerative diseases.8

In addition to its potential as a neurotransmitter transport protein, SLC12 has also been shown to play a role in the transport of other molecules, including ions and small molecules.9

Conclusion

Solute Carrier Family 12 (SLC12) is a transmembrane protein that is involved in various physiological processes, including cell signaling and disease progression. Its potential as a drug target and biomarker has been identified in various studies, including its involvement in cancer and neurodegenerative diseases. Further research is needed to fully understand the biology of SLC12 and its potential as a drug target and biomarker.

Protein Name: Solute Carrier Family 12 (nonspecified Subtype)

The "Solute Carrier Family 12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Solute Carrier Family 12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets